Protara Therapeutics, Inc. (TARA)
2.70
-0.06
(-2.17%)
USD |
NASDAQ |
Oct 02, 16:00
2.695
0.00 (0.00%)
After-Hours: 20:00
Protara Therapeutics Net Income (Quarterly) : -21.67M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -21.67M |
| March 31, 2026 | -17.78M |
| December 31, 2025 | -17.31M |
| September 30, 2025 | -13.26M |
| June 30, 2025 | -14.96M |
| March 31, 2025 | -11.91M |
| December 31, 2024 | -12.77M |
| September 30, 2024 | -11.22M |
| June 30, 2024 | -9.513M |
| March 31, 2024 | -11.10M |
| December 31, 2023 | -10.22M |
| September 30, 2023 | -9.86M |
| June 30, 2023 | -11.29M |
| March 31, 2023 | -9.045M |
| December 31, 2022 | -38.97M |
| September 30, 2022 | -7.691M |
| June 30, 2022 | -8.539M |
| March 31, 2022 | -10.76M |
| December 31, 2021 | -10.23M |
| September 30, 2021 | -10.78M |
| June 30, 2021 | -12.78M |
| March 31, 2021 | -13.46M |
| December 31, 2020 | -8.808M |
| September 30, 2020 | -7.970M |
| June 30, 2020 | -7.14M |
| Date | Value |
|---|---|
| March 31, 2020 | -10.06M |
| December 31, 2019 | -2.519M |
| September 30, 2019 | -2.354M |
| June 30, 2019 | -1.429M |
| March 31, 2019 | -1.528M |
| December 31, 2018 | -5.259M |
| September 30, 2018 | -4.51M |
| June 30, 2018 | -4.879M |
| March 31, 2018 | -6.081M |
| December 31, 2017 | -5.551M |
| September 30, 2017 | -12.31M |
| June 30, 2017 | -5.608M |
| March 31, 2017 | -6.498M |
| December 31, 2016 | -6.962M |
| September 30, 2016 | -7.107M |
| June 30, 2016 | -7.905M |
| March 31, 2016 | -6.552M |
| December 31, 2015 | -6.342M |
| September 30, 2015 | -5.383M |
| June 30, 2015 | -5.072M |
| March 31, 2015 | -4.58M |
| December 31, 2014 | 7.233M |
| September 30, 2014 | -5.181M |
| June 30, 2014 | -2.563M |
| March 31, 2014 | -2.831M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| NovelStem International Corp. | -0.0858M |
| Brainstorm Cell Therapeutics, Inc. | -3.855M |
| Summit Therapeutics, Inc. | -215.70M |
| Kezar Life Sciences, Inc. | -5.756M |
| Clene, Inc. | -13.42M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 21.67M |
| EPS Diluted (Quarterly) | -0.3552 |
| Enterprise Value | 19.78M |
| Earnings Yield | -50.14% |
| Normalized Earnings Yield | -50.14 |